Ferroptosis inducer-13
Ferroptosis inducer-13 is a 5′-prenylated chalcone derivative that effectively induces ferroptosis in human non-small cell lung cancer (NSCLC) cells by altering the activity of the Nrf2/xCT/GPX4 pathway. Ferroptosis inducer-13 exhibits potent anti-proliferative effects in vitro, and inhibits tumour growth in a NSCLC mouse model. Ferroptosis inducer-13 can be used for NSCLC research.
For research use only. We do not sell to patients.
- CAS No.: 3085517-19-4
- Formula: C21H23NO3
- Molecular Weight:337.41
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
|
GPX4 |
Ferroptosis inducer-13 (compound 4a) (72 h) exhibits potent broad-spectrum antiproliferative activity against cancer cells, with IC50 values of 2.11 μM (PC9), 2.17 μM (MDA-MB-231), 3.81 μM (SMMC-7721), and 4.10 μM (SGC-7901)[1].
Ferroptosis inducer-13 (0-40 μM; 24-72 h) exhibits significant anti-proliferative effects on NSCLC cells (PC9 and H1975) in a time- and concentration-dependent manner[1].
Ferroptosis inducer-13 (20 μM; 24 h) induces ferroptosis in NSCLC cells (PC9 and H1975)[1].
Ferroptosis inducer-13 (0-40 μM; 24 h) leads to GSH depletion and increases Fe2+, ROS and LPO levels, and induces ferroptosis through modulation of the Nrf2/xCT/GPX4 signaling pathway in PC9 and H1975 cells[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:PC9, H1975
-
Concentration:0, 2.5, 5, 10, 20, 40 μM
-
Incubation Time:24, 48, 72 h
-
Result:Gradually decreased cell viability of PC9 and H1975 cells in a concentration manner.
Exhibited significant anti-proliferative effects on NSCLC cells (PC9 and H1975) in a time- and concentration-dependent manner.
-
Cell Line:PC9, H1975
-
Concentration:20 μM
-
Incubation Time:12 h
-
Result:Significantly enhanced cell viability by approximately 20% when combined with ferroptosis inhibitor.
-
Cell Line:PC9, H1975
-
Concentration:20 μM
-
Incubation Time:24 h
-
Result:Moderately reversed the GPX expression when combined with ferroptosis inhibitor.
-
Cell Line:PC9, H1975
-
Concentration:0, 5, 10, 20, 40 μM
-
Incubation Time:24 h
-
Result:Significantly decreased Nrf2 levels in both cytoplasmic and nuclear fractions while reducing xCT and GPX4 expression.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female Balb/c nude mice (16-20 g) subcutaneously injected with PC9 cells[1]
-
Dosage:2, 5 mg/kg
-
Administration:i.p.; every 3 days for 18 days
-
Result:Exhibited tumor growth suppression with minimal impact on body weight.
Caused no significant organ toxicity in mice.
Significantly downregulated the protein expression of xCT and GPX4 in tumor tissues compared with the control group.
Chemical Information
-
CAS No. 3085517-19-4
-
Molecular Weight 337.41
-
Formula C21H23NO3
-
SMILES
COC1=CC(OC)=C(C=C1C(/C=C/C2=NC=CC=C2)=O)C/C=C(C)\C
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Ferroptosis inducer-13 Related Classifications
HY-179481 Related Classifications
Powered by Bioz